Compare ZDAI & ADVB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ZDAI | ADVB |
|---|---|---|
| Founded | 2022 | 2014 |
| Country | Hong Kong | Hong Kong |
| Employees | N/A | N/A |
| Industry | General Bldg Contractors - Nonresidential Bldgs | Medical Specialities |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 8.6M |
| IPO Year | 2023 | 2023 |
| Metric | ZDAI | ADVB |
|---|---|---|
| Price | $1.12 | $2.38 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 5.1K | ★ 32.9K |
| Earning Date | 08-17-2026 | 11-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 3431.25 |
| EPS | N/A | ★ 5.33 |
| Revenue | N/A | ★ $127,637.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | $0.53 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.20 | $2.71 |
| 52 Week High | $11.48 | $113.80 |
| Indicator | ZDAI | ADVB |
|---|---|---|
| Relative Strength Index (RSI) | 35.81 | 20.77 |
| Support Level | $0.34 | N/A |
| Resistance Level | $1.77 | $5.59 |
| Average True Range (ATR) | 0.11 | 0.58 |
| MACD | -0.00 | -0.10 |
| Stochastic Oscillator | 4.55 | 3.90 |
DirectBooking Technology Co Ltd, formerly Primega Group Holdings Ltd is engaged in transportation services. It operates in the Hong Kong construction industry, mainly handling the transportation of materials excavated from construction sites. Its services principally comprise (i) soil and rock transportation services; (ii) diesel oil trading; and (iii) construction works, which mainly include ELS works and bored piling. The company provide services as a subcontractor to other construction contractors in Hong Kong. Maximum revenue is generated from soil and rock transportation services.
Advanced Biomed Inc operates through its subsidiaries and is mainly engaged in the research and development of various original microfluidic biochip technologies and the provision of tumor precision diagnosis and treatment technology applications. Through the joint application of semiconductor technology and biotechnology, it has developed various technologies and testing equipment for early screening and detection, diagnosis and staging, and treatment of cancer. Its devices: A+Pre, AC-1000, A+CellScan, and A+SCDrop, and three corresponding microfluidic biochips, A+Pre Chip and AC-1000 CTC Enrichment Chip, and A+CellScan Chip, are designed to provide rapid and affordable assay products and services to cancer patients.